BMS re-ups 'highly productive' legacy neurodegeneration partnership with Evotec for $50M upfront

BMS re-ups 'highly productive' legacy neurodegeneration partnership with Evotec for $50M upfront

Source: 
Fierce Biotech
snippet: 

Things must be going well for Bristol Myers Squibb’s legacy Celgene-Evotec neurodegeneration partnership. The New York Big Pharma has decided to add another eight years to their agreement, boosting the overall potential deal value to $4 billion.